Navigation Links
Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Date:9/5/2007

KANNAPOLIS, N.C., Sept. 5 /PRNewswire/ -- A study in the August 2007 issue of Pediatric Diabetes supports the use of the GlycoMark 1,5-anhydroglucitol (1,5-AG) blood test to evaluate therapy in children with diabetes, especially to target postprandial hyperglycemia (elevated after-meal glucose levels). Controlling after-meal glucose levels is important in achieving optimal glycemic control and reducing the burden of cardiovascular complications, the leading cause of death in patients. The data in this study were similar to previous studies in adults.

The study was completed by Rubina Heptulla, MD, from the Department of Pediatrics, Division of Endocrinology and Metabolism at the Baylor College of Medicine and Texas Children's Hospital in Houston, Texas. "These data further demonstrate that the 1,5-AG test is an effective measure of postprandial glucose concentrations and is particularly important in evaluating therapies which have shown efficacy in controlling postprandial hyperglycemia such as exenatide, pramlintide, and sitagliptin," said Dr. Heptulla. "We were also able to demonstrate that the normal range of 1,5-AG in children was similar to normal adults reported in previous studies."

The results of this study are consistent with previous studies reported in adults. In a recent study published in the American Diabetes Association Diabetes Care journal (Dungan et al. Diabetes Care 2006; 29 (6): 1214-1219), it was shown that the GlycoMark 1,5-AG test reflected after-meal glucose levels more robustly than the A1C test. The study also showed that GlycoMark was able to reveal dramatically different after-meal glucose levels in patients with similar A1C levels.

Moreover, studies recently presented at the 67th Annual 2007 Scientific Sessions of the American Diabetes Association and other meetings show that GlycoMark is particularly valuable in detecting underlying treatment effects of agents such as exenatide (Byetta) and pramlintide (Symlin) which were not revealed by the gold standard hemoglobin A1C test. These findings have important implications for patient care and pharmaceutical research as the reduction of after-meal glucose rises is a key objective of diabetes drug therapy.

About GlycoMark

GlycoMark is an FDA approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5-AG) in blood. Multiple published studies in peer-reviewed journals have shown that the 1,5-AG test is a specific index of postprandial hyperglycemia (elevated after-meal glucose levels) and short-term glycemic control -- providing a useful complement to A1C testing. GlycoMark is being used in clinical practices nationwide and is available at major reference laboratories including Quest Diagnostics, LabCorp, Esoterix, Mayo Medical Laboratories, ARUP Laboratories, and Specialty Laboratories. The test is also available at most major contract research organizations for pharmaceutical research studies.

GlycoMark is being commercialized by a partnership between Toyota Tsusho America (New York, NY), Nippon Kayaku (Tokyo, Japan) and the BioMarker Group (Kannapolis, NC). GlycoMark activities are centered in the North Carolina Research Campus in Kannapolis, North Carolina, a 350-acre life sciences hub started by billionaire David H. Murdock.

More information about GlycoMark may be found at http://www.glycomark.com.


'/>"/>
SOURCE GlycoMark
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  Alkahest Inc. ... treatments for neurodegenerative diseases and other age-related conditions, ... the company as Chief Medical Officer. In this ... clinical development activities at Alkahest and serve on ... most recently served as Executive Director at Dynavax, ...
(Date:1/23/2017)... ... January 23, 2017 , ... CallTower is proud to announce ... of the Year Award winner for 2017. , For three consecutive years, CallTower ... In 2016, CallTower was awarded with the hosted VoIP Excellence award and in 2015, ...
(Date:1/21/2017)... ... January 20, 2017 , ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. ... will receive exclusive marketing and sales rights for all non-OEM Transonic products in Japan. ... in Japan, the new Nipro - Transonic JV is a natural next step to ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
Breaking Biology Technology:
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):